OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis
Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, et al.
Liver Cancer (2016) Vol. 5, Iss. 3, pp. 175-189
Open Access | Times Cited: 30
Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, et al.
Liver Cancer (2016) Vol. 5, Iss. 3, pp. 175-189
Open Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 496
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 496
Report of the 20th Nationwide follow‐up survey of primary liver cancer in Japan
Masatoshi Kudo, Namiki Izumi, Shoji Kubo, et al.
Hepatology Research (2019) Vol. 50, Iss. 1, pp. 15-46
Open Access | Times Cited: 144
Masatoshi Kudo, Namiki Izumi, Shoji Kubo, et al.
Hepatology Research (2019) Vol. 50, Iss. 1, pp. 15-46
Open Access | Times Cited: 144
Systemic Therapy for Hepatocellular Carcinoma: 2017 Update
Masatoshi Kudo
Oncology (2017) Vol. 93, Iss. Suppl. 1, pp. 135-146
Open Access | Times Cited: 114
Masatoshi Kudo
Oncology (2017) Vol. 93, Iss. Suppl. 1, pp. 135-146
Open Access | Times Cited: 114
Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma
Masaya Sato, Kentaro Morimoto, Shigeki Kajihara, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 109
Masaya Sato, Kentaro Morimoto, Shigeki Kajihara, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 109
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)
Masatoshi Kudo, Namiki Izumi, Norihiro Kokudo, et al.
Hepatology Research (2020) Vol. 51, Iss. 4, pp. 355-405
Open Access | Times Cited: 85
Masatoshi Kudo, Namiki Izumi, Norihiro Kokudo, et al.
Hepatology Research (2020) Vol. 51, Iss. 4, pp. 355-405
Open Access | Times Cited: 85
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)
Masatoshi Kudo, Namiki Izumi, Norihiro Kokudo, et al.
Hepatology Research (2021) Vol. 52, Iss. 1, pp. 5-66
Open Access | Times Cited: 69
Masatoshi Kudo, Namiki Izumi, Norihiro Kokudo, et al.
Hepatology Research (2021) Vol. 52, Iss. 1, pp. 5-66
Open Access | Times Cited: 69
Management of Hepatocellular Carcinoma in Japan as a World-Leading Model
Masatoshi Kudo
Liver Cancer (2017) Vol. 7, Iss. 2, pp. 134-147
Open Access | Times Cited: 73
Masatoshi Kudo
Liver Cancer (2017) Vol. 7, Iss. 2, pp. 134-147
Open Access | Times Cited: 73
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Takashi Niizeki, Takayuki Tokunaga, Yuko Takami, et al.
Targeted Oncology (2022) Vol. 17, Iss. 6, pp. 643-653
Open Access | Times Cited: 31
Takashi Niizeki, Takayuki Tokunaga, Yuko Takami, et al.
Targeted Oncology (2022) Vol. 17, Iss. 6, pp. 643-653
Open Access | Times Cited: 31
Report of the 23rd nationwide follow‐up survey of primary liver cancer in Japan (2014–2015)
Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, et al.
Hepatology Research (2023) Vol. 53, Iss. 10, pp. 895-959
Open Access | Times Cited: 20
Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, et al.
Hepatology Research (2023) Vol. 53, Iss. 10, pp. 895-959
Open Access | Times Cited: 20
Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma
Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4763-4763
Open Access | Times Cited: 19
Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4763-4763
Open Access | Times Cited: 19
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching
Shigeo Shimose, Masatoshi Tanaka, Hideki Iwamoto, et al.
Hepatology Research (2019) Vol. 49, Iss. 8, pp. 919-928
Closed Access | Times Cited: 45
Shigeo Shimose, Masatoshi Tanaka, Hideki Iwamoto, et al.
Hepatology Research (2019) Vol. 49, Iss. 8, pp. 919-928
Closed Access | Times Cited: 45
Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update
Masatoshi Kudo
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 167-180
Open Access | Times Cited: 21
Masatoshi Kudo
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 167-180
Open Access | Times Cited: 21
Tumor-suppressing miR-141 gene complex-loaded tissue-adhesive glue for the locoregional treatment of hepatocellular carcinoma
Minkyoung Kim, Young-Ah Moon, Chung Kil Song, et al.
Theranostics (2018) Vol. 8, Iss. 14, pp. 3891-3901
Open Access | Times Cited: 21
Minkyoung Kim, Young-Ah Moon, Chung Kil Song, et al.
Theranostics (2018) Vol. 8, Iss. 14, pp. 3891-3901
Open Access | Times Cited: 21
Structure, molecular modification and anti-tumor activity of melanin from Lachnum singerianum
Ziyang Ye, Ying Lu, Shuai Zong, et al.
Process Biochemistry (2018) Vol. 76, pp. 203-212
Closed Access | Times Cited: 21
Ziyang Ye, Ying Lu, Shuai Zong, et al.
Process Biochemistry (2018) Vol. 76, pp. 203-212
Closed Access | Times Cited: 21
Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview
Maria Tampaki, George Papatheodoridis, Εvangelos Cholongitas
Cancers (2023) Vol. 15, Iss. 4, pp. 1310-1310
Open Access | Times Cited: 7
Maria Tampaki, George Papatheodoridis, Εvangelos Cholongitas
Cancers (2023) Vol. 15, Iss. 4, pp. 1310-1310
Open Access | Times Cited: 7
Management of Hepatocellular Carcinoma in Japan: Current Trends
Masatoshi Kudo
Liver Cancer (2019) Vol. 9, Iss. 1, pp. 1-5
Open Access | Times Cited: 19
Masatoshi Kudo
Liver Cancer (2019) Vol. 9, Iss. 1, pp. 1-5
Open Access | Times Cited: 19
Analysis of the Safety and Effectiveness of Lenvatinib + TACE-HAIC + PD-1 Inhibitor for Intermediate and Advanced Hepatocellular Carcinoma
Yuguang Yang, Hui Tang, Cong Mai, et al.
Letters in Drug Design & Discovery (2023) Vol. 21, Iss. 11, pp. 2035-2045
Closed Access | Times Cited: 6
Yuguang Yang, Hui Tang, Cong Mai, et al.
Letters in Drug Design & Discovery (2023) Vol. 21, Iss. 11, pp. 2035-2045
Closed Access | Times Cited: 6
第20回 全国原発性肝癌追跡調査報告（2008～2009）
工藤 正俊, 泉 並木, 久保 正二, et al.
Kanzo (2019) Vol. 60, Iss. 8, pp. 258-293
Open Access | Times Cited: 15
工藤 正俊, 泉 並木, 久保 正二, et al.
Kanzo (2019) Vol. 60, Iss. 8, pp. 258-293
Open Access | Times Cited: 15
Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database
Jae Seung Lee, In Rae Cho, Hye Won Lee, et al.
Cancer Research and Treatment (2019) Vol. 51, Iss. 4, pp. 1347-1356
Open Access | Times Cited: 10
Jae Seung Lee, In Rae Cho, Hye Won Lee, et al.
Cancer Research and Treatment (2019) Vol. 51, Iss. 4, pp. 1347-1356
Open Access | Times Cited: 10
Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors
Masatoshi Kudo
Digestive Diseases (2016) Vol. 34, Iss. 6, pp. 714-730
Closed Access | Times Cited: 9
Masatoshi Kudo
Digestive Diseases (2016) Vol. 34, Iss. 6, pp. 714-730
Closed Access | Times Cited: 9
<p>Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve</p>
Nicholas Fidelman, Curt Johanson, Maureen P. Kohi, et al.
Journal of Hepatocellular Carcinoma (2019) Vol. Volume 6, pp. 93-103
Open Access | Times Cited: 9
Nicholas Fidelman, Curt Johanson, Maureen P. Kohi, et al.
Journal of Hepatocellular Carcinoma (2019) Vol. Volume 6, pp. 93-103
Open Access | Times Cited: 9
Matching Graft Quality to Recipient’s Disease Severity Based on the Survival Benefit in Liver Transplantation
Audrey Winter, Cyrille Féray, Corinne Antoine, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Audrey Winter, Cyrille Féray, Corinne Antoine, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey
Khalid Mumtaz, Nishi Patel, Rohan M. Modi, et al.
Hepatobiliary & pancreatic diseases international (2017) Vol. 16, Iss. 6, pp. 624-630
Closed Access | Times Cited: 5
Khalid Mumtaz, Nishi Patel, Rohan M. Modi, et al.
Hepatobiliary & pancreatic diseases international (2017) Vol. 16, Iss. 6, pp. 624-630
Closed Access | Times Cited: 5
第21回 全国原発性肝癌追跡調査報告（2010～2011）
工藤 正俊, 泉 並木, 久保 正二, et al.
Kanzo (2020) Vol. 61, Iss. 12, pp. 645-691
Open Access | Times Cited: 5
工藤 正俊, 泉 並木, 久保 正二, et al.
Kanzo (2020) Vol. 61, Iss. 12, pp. 645-691
Open Access | Times Cited: 5
Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma
R. Peter Lokken, Robert K. Kerlan, Yu-Che Chung, et al.
American Journal of Roentgenology (2021) Vol. 216, Iss. 5, pp. 1283-1290
Closed Access | Times Cited: 5
R. Peter Lokken, Robert K. Kerlan, Yu-Che Chung, et al.
American Journal of Roentgenology (2021) Vol. 216, Iss. 5, pp. 1283-1290
Closed Access | Times Cited: 5
